---
title: "SJFW released its semi-annual performance, with a net loss attributable to the parent company of 7.14 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255179532.md"
description: "According to the Zhitong Finance APP, SJFW disclosed its semi-annual report for 2025, showing that the company achieved revenue of 216 million yuan during the reporting period, a year-on-year decrease of 9.04%; the net profit attributable to shareholders was a loss of 7.14 million yuan; the net profit excluding non-recurring gains and losses was a loss of 8.03 million yuan; basic earnings per share were -0.01 yuan"
datetime: "2025-08-29T10:49:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255179532.md)
  - [en](https://longbridge.com/en/news/255179532.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255179532.md)
generator: "portal-rs"
---

# SJFW released its semi-annual performance, with a net loss attributable to the parent company of 7.14 million yuan

According to the Zhitong Finance APP, SJFW (600616.SH) disclosed its semi-annual report for 2025, showing that the company achieved revenue of 216 million yuan during the reporting period, a year-on-year decrease of 9.04%; the net profit attributable to shareholders was a loss of 7.14 million yuan; the net profit excluding non-recurring gains and losses was a loss of 8.03 million yuan; basic earnings per share were -0.01 yuan

### Related Stocks

- [600616.CN](https://longbridge.com/en/quote/600616.CN.md)

## Related News & Research

- [Promise Analyzes Telehealth Licensing Rules as Compact Hits Record 3,633 Licenses in a Month](https://longbridge.com/en/news/296635882.md)
- [ULTP: Proprietary brand sales rose 5.3% as revenues fell 3.5%, with FY27 outlook remaining cautious](https://longbridge.com/en/news/296308991.md)
- [BEER: H1 2026 saw 22% sales volume growth, 15% revenue growth, and a €7M expansion investment](https://longbridge.com/en/news/296622535.md)
- [Curql invests in pet healthcare platform Wagmo](https://longbridge.com/en/news/296396050.md)
- [09:02 ETEvolved By Nature's Peptide Platform Used in FDA-Cleared Prescription Therapy for the Management of Atopic Dermatitis](https://longbridge.com/en/news/296496101.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**